vs

Side-by-side financial comparison of Bunge Global (BG) and MEDIFAST INC (MED). Click either name above to swap in a different company.

Bunge Global is the larger business by last-quarter revenue ($4.9B vs $75.1M, roughly 65.1× MEDIFAST INC). On growth, Bunge Global posted the faster year-over-year revenue change (22.2% vs -36.9%). Bunge Global produced more free cash flow last quarter ($809.0M vs $-6.6M). Over the past eight quarters, Bunge Global's revenue compounded faster (11.3% CAGR vs -34.4%).

Bunge Global SA (BUN-ghee) is a global agribusiness and food company, incorporated in Geneva, Switzerland and headquartered in St. Louis, Missouri, United States.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

BG vs MED — Head-to-Head

Bigger by revenue
BG
BG
65.1× larger
BG
$4.9B
$75.1M
MED
Growing faster (revenue YoY)
BG
BG
+59.1% gap
BG
22.2%
-36.9%
MED
More free cash flow
BG
BG
$815.6M more FCF
BG
$809.0M
$-6.6M
MED
Faster 2-yr revenue CAGR
BG
BG
Annualised
BG
11.3%
-34.4%
MED

Income Statement — Q4 2025 vs Q4 2025

Metric
BG
BG
MED
MED
Revenue
$4.9B
$75.1M
Net Profit
$95.0M
Gross Margin
20.7%
69.4%
Operating Margin
1.8%
-10.4%
Net Margin
1.9%
Revenue YoY
22.2%
-36.9%
Net Profit YoY
-84.2%
EPS (diluted)
$-0.02
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BG
BG
MED
MED
Q4 25
$4.9B
$75.1M
Q3 25
$4.4B
$89.4M
Q2 25
$4.0B
$105.6M
Q1 25
$3.7B
$115.7M
Q4 24
$4.0B
$119.0M
Q3 24
$3.9B
$140.2M
Q2 24
$3.7B
$168.6M
Q1 24
$3.9B
$174.7M
Net Profit
BG
BG
MED
MED
Q4 25
$95.0M
Q3 25
$166.0M
$-2.3M
Q2 25
$354.0M
$2.5M
Q1 25
$201.0M
$-772.0K
Q4 24
$602.0M
Q3 24
$221.0M
$1.1M
Q2 24
$70.0M
$-8.2M
Q1 24
$244.0M
$8.3M
Gross Margin
BG
BG
MED
MED
Q4 25
20.7%
69.4%
Q3 25
24.3%
69.5%
Q2 25
18.4%
72.6%
Q1 25
16.3%
72.8%
Q4 24
27.0%
74.1%
Q3 24
19.9%
75.4%
Q2 24
17.8%
73.2%
Q1 24
22.2%
72.8%
Operating Margin
BG
BG
MED
MED
Q4 25
1.8%
-10.4%
Q3 25
6.2%
-4.6%
Q2 25
12.3%
-1.0%
Q1 25
7.8%
-1.1%
Q4 24
18.3%
0.6%
Q3 24
8.3%
1.5%
Q2 24
2.8%
-4.7%
Q1 24
9.4%
4.5%
Net Margin
BG
BG
MED
MED
Q4 25
1.9%
Q3 25
3.8%
-2.5%
Q2 25
8.8%
2.3%
Q1 25
5.5%
-0.7%
Q4 24
15.0%
Q3 24
5.7%
0.8%
Q2 24
1.9%
-4.8%
Q1 24
6.2%
4.8%
EPS (diluted)
BG
BG
MED
MED
Q4 25
$-0.02
$-1.64
Q3 25
$0.84
$-0.21
Q2 25
$2.61
$0.22
Q1 25
$1.48
$-0.07
Q4 24
$4.27
$0.08
Q3 24
$1.56
$0.10
Q2 24
$0.48
$-0.75
Q1 24
$1.68
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BG
BG
MED
MED
Cash + ST InvestmentsLiquidity on hand
$2.0B
$167.3M
Total DebtLower is stronger
$10.2B
Stockholders' EquityBook value
$15.9B
$198.9M
Total Assets
$44.5B
$248.0M
Debt / EquityLower = less leverage
0.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BG
BG
MED
MED
Q4 25
$2.0B
$167.3M
Q3 25
$3.2B
$173.5M
Q2 25
$7.1B
$162.7M
Q1 25
$3.9B
$164.6M
Q4 24
$3.8B
$162.3M
Q3 24
$3.0B
$170.0M
Q2 24
$1.3B
$163.5M
Q1 24
$3.1B
$156.4M
Total Debt
BG
BG
MED
MED
Q4 25
$10.2B
Q3 25
$11.1B
Q2 25
$7.7B
Q1 25
$5.4B
Q4 24
$5.4B
Q3 24
$5.4B
Q2 24
$4.1B
Q1 24
$4.1B
Stockholders' Equity
BG
BG
MED
MED
Q4 25
$15.9B
$198.9M
Q3 25
$15.8B
$214.7M
Q2 25
$10.9B
$216.0M
Q1 25
$10.6B
$211.0M
Q4 24
$9.9B
$210.1M
Q3 24
$10.1B
$207.3M
Q2 24
$10.0B
$205.3M
Q1 24
$10.6B
$211.0M
Total Assets
BG
BG
MED
MED
Q4 25
$44.5B
$248.0M
Q3 25
$46.3B
$268.2M
Q2 25
$31.2B
$269.3M
Q1 25
$26.7B
$280.0M
Q4 24
$24.9B
$284.2M
Q3 24
$25.3B
$291.2M
Q2 24
$24.4B
$293.5M
Q1 24
$25.8B
$302.8M
Debt / Equity
BG
BG
MED
MED
Q4 25
0.64×
Q3 25
0.71×
Q2 25
0.71×
Q1 25
0.51×
Q4 24
0.54×
Q3 24
0.54×
Q2 24
0.41×
Q1 24
0.39×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BG
BG
MED
MED
Operating Cash FlowLast quarter
$1.3B
$-5.3M
Free Cash FlowOCF − Capex
$809.0M
$-6.6M
FCF MarginFCF / Revenue
16.6%
-8.8%
Capex IntensityCapex / Revenue
11.0%
1.8%
Cash ConversionOCF / Net Profit
14.18×
TTM Free Cash FlowTrailing 4 quarters
$-879.0M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BG
BG
MED
MED
Q4 25
$1.3B
$-5.3M
Q3 25
$854.0M
$12.1M
Q2 25
$-1.1B
$-3.4M
Q1 25
$-285.0M
$3.4M
Q4 24
$1.1B
$-4.9M
Q3 24
$1.3B
$9.1M
Q2 24
$-1.5B
$13.1M
Q1 24
$994.0M
$7.3M
Free Cash Flow
BG
BG
MED
MED
Q4 25
$809.0M
$-6.6M
Q3 25
$385.0M
$10.8M
Q2 25
$-1.5B
$-4.8M
Q1 25
$-595.0M
$1.9M
Q4 24
$564.0M
$-7.2M
Q3 24
$973.0M
$7.7M
Q2 24
$-1.8B
$11.1M
Q1 24
$758.0M
$5.4M
FCF Margin
BG
BG
MED
MED
Q4 25
16.6%
-8.8%
Q3 25
8.8%
12.0%
Q2 25
-36.8%
-4.5%
Q1 25
-16.2%
1.6%
Q4 24
14.1%
-6.1%
Q3 24
25.1%
5.5%
Q2 24
-47.4%
6.6%
Q1 24
19.2%
3.1%
Capex Intensity
BG
BG
MED
MED
Q4 25
11.0%
1.8%
Q3 25
10.7%
1.5%
Q2 25
10.1%
1.3%
Q1 25
8.5%
1.3%
Q4 24
12.2%
1.9%
Q3 24
9.1%
1.0%
Q2 24
8.0%
1.1%
Q1 24
6.0%
1.1%
Cash Conversion
BG
BG
MED
MED
Q4 25
14.18×
Q3 25
5.14×
Q2 25
-3.03×
-1.36×
Q1 25
-1.42×
Q4 24
1.75×
Q3 24
6.00×
8.04×
Q2 24
-21.06×
Q1 24
4.07×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BG
BG

Other Oilseeds Processing And Refining$4.6B95%
Other$251.0M5%
Other Products$3.0M0%

MED
MED

Segment breakdown not available.

Related Comparisons